These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 22706117)

  • 1. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of inhibitors of poly(ADP-ribose) polymerase.
    Calvert H; Azzariti A
    Ann Oncol; 2011 Jan; 22 Suppl 1():i53-9. PubMed ID: 21285153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
    Ashworth A
    J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducing synthetic lethality using PARP inhibitors.
    Boss DS; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
    Chalmers AJ; Lakshman M; Chan N; Bristow RG
    Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
    Mercier-Vogel L; Bodmer A; Castiglione M
    Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DNA damaging revolution.
    Cetin B; Wabl CA; Gumusay O
    Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
    Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
    PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    Gaziev AI
    Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research progresses of the PARP inhibitors for the treatment of cancer].
    He YJ; Liu RH; Ning CQ; Yu NF
    Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.